Publications by authors named "Nehali D Patel"
Article Synopsis
- * Conducted on healthy volunteers, the study found that SJ733 was well-tolerated with no serious side effects, and the boosted regimen significantly increased drug exposure compared to unboosted doses.
- * The findings promote the continued development of SJ733 and introduce a new strategy to improve antimalarial treatment by enhancing drug pharmacokinetics through a boosting agent.
Rapid Start of Antiretroviral Therapy in Youth Diagnosed with HIV Infection.
Pediatr Infect Dis J
February 2021
Background: Guidelines for the use of antiretroviral agents in adults and adolescents with HIV recommend that antiretroviral therapy (ART) be started as soon as possible. While rapid initiation of ART in adults with HIV has been well-described, there is relatively little information describing this approach for youth.
Methods: On April 1, 2018, St.
Background: (+)-SJ000557733 (SJ733) is a novel, orally bioavailable inhibitor of Plasmodium falciparum ATP4. In this first-in-human and induced blood-stage malaria phase 1a/b trial, we investigated the safety, tolerability, pharmacokinetics, and antimalarial activity of SJ733 in humans.
Methods: The phase 1a was a single-centre, dose-escalation, first-in-human study of SJ733 allowing modifications to dose increments and dose-cohort size on the basis of safety and pharmacokinetic results.